Print this page
breast
-
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL, Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy.
Protocol: 111911Principal Investigator:
-
Marissa Botwinick
Applicable Disease Sites: Any Site -
A Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma.
Protocol: 111914Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Brain and Nervous System -
A Phase 3 Study of Selumetinib or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations.
Protocol: 112102Principal Investigator:
-
Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor.
Protocol: 112104Principal Investigator:
-
Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
A Randomized Phase 3 Trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma.
Protocol: 112105Principal Investigator:
-
Archana Sharma
Applicable Disease Sites: Any Site
Lymphoid Leukemia -
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
Protocol: 112106Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Kidney -
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG).
Protocol: 112203Principal Investigator:
-
Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma.
Protocol: 112205Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Soft Tissue -
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma.
Protocol: 112305Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Hodgkin's Lymphoma -
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors.
Protocol: 112306Principal Investigator:
-
Peter D. Cole
Applicable Disease Sites: Brain and Nervous System -
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy.
Protocol: 112308Principal Investigator:
-
Marissa Botwinick
Applicable Disease Sites: Leukemia, other -
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC).
Protocol: 112405Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
ACNS2321: A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas
Protocol: 112409Principal Investigator:
-
Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
The Women's Circle of Health Study.
Protocol: 130404Principal Investigator:
-
Elisa V Bandera
Applicable Disease Sites: Breast - Female -
Adapting and Implementing Evidence-Based Breast Cancer Follow-up in Primary Care.
Protocol: 132103Principal Investigator:
-
Shawna Hudson
Applicable Disease Sites: Breast -
Cancer Analytics and South Asian Health Breast Cancer Survivor Study (CANSAH-BC).
Protocol: 132204Applicable Disease Sites: Breast